Lattice_grid_med
Powered by LatticeGrid

Search Enter term and hit return. Use '*' for as a wildcard.

Publication Listing for the MeSH term Endometrial cancer. Found 9 abstracts

Papatla K, Houck KL, Hernandez E, Chu C, Rubin S. Second primary uterine malignancies after radiation therapy for cervical cancer. Archives of gynecology and obstetrics. 2019 Aug;300(2):389-94.
Westin SN, Sill MW, Coleman RL, Waggoner S, Moore KN, Mathews CA, Martin LP, Modesitt SC, Lee S, Ju Z, Mills GB, Schilder RJ, Fracasso PM, Birrer MJ, Aghajanian C. Safety lead-in of the MEK inhibitor trametinib in combination with GSK2141795, an AKT inhibitor, in patients with recurrent endometrial cancer: An NRG Oncology/GOG study. Gynecol Oncol. 2019 Oct 15;155(3):420-8.   PMCID: PMC6922584
Jordan SE, Micaily I, Hernandez E, Ferriss JS, Miyamoto CT, Li S, Micaily B. Image-guided high-dose-rate intracavitary brachytherapy in the treatment of medically inoperable early-stage endometrioid type endometrial adenocarcinoma. Brachytherapy. 2017 Nov;16(6):1144-51.
Jordan SE, Micaily I, Hernandez E, Ferriss JS, Miyamoto CT, Li S, Micaily B. Image-guided high-dose-rate intracavitary brachytherapy in the treatment of medically inoperable early-stage endometrioid type endometrial adenocarcinoma. Brachytherapy. 2017 Nov;16(6):1144-51.
Jordan SE, Micaily I, Hernandez E, Ferriss JS, Miyamoto CT, Li S, Micaily B. Image-guided high-dose-rate intracavitary brachytherapy in the treatment of medically inoperable early-stage endometrioid type endometrial adenocarcinoma. Brachytherapy. 2017 Nov;16(6):1144-51.
Haggerty AF, Huepenbecker S, Sarwer DB, Spitzer J, Raggio G, Chu CS, Ko E, Allison KC. The use of novel technology-based weight loss interventions for obese women with endometrial hyperplasia and cancer. Gynecol Oncol. 2016 Feb;140(2):239-44.
Shaikh T, Churilla TM, Mantia-Smaldone GM, Chu C, Rubin SC, Anderson PR. The role of adjuvant radiation in lymph node positive endometrial adenocarcinoma. Gynecol Oncol. 2016 Jun;141(3):434-9.
Matulonis U, Vergote I, Backes F, Martin LP, McMeekin S, Birrer M, Campana F, Xu Y, Egile C, Ghamande S. Phase II study of the PI3K inhibitor pilaralisib (SAR245408; XL147) in patients with advanced or recurrent endometrial carcinoma. Gynecol Oncol. 2015 Feb;136(2):246-53.
Matulonis U, Vergote I, Backes F, Martin LP, McMeekin S, Birrer M, Campana F, Xu Y, Egile C, Ghamande S. Phase II study of the PI3K inhibitor pilaralisib (SAR245408; XL147) in patients with advanced or recurrent endometrial carcinoma. Gynecol Oncol. 2015 Jan;136(2):246-53.
The above publications are sorted by year, faculty last name, and first author. Click on any highlighted author listed to find all publications attributed to that individual. Click on the publication title to see the abstract. First authors who are faculty are highlighted like this. Last authors who are faculty are highlighted like this. Other authors who are faculty are highlighted like this.

MeSH cloud from publications including the MeSH term Endometrial cancer

Last updated on Monday, July 13, 2020